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Calciﬁc aortic valve disease (CAVD), once thought to be a degenerative disease, is now recognized to be an active pathobiological
process, with chronic inﬂammation emerging as a predominant, and possibly driving, factor. However, many details of the pa-
thobiological mechanisms of CAVD remain to be described, and new approaches to treat CAVD need to be identiﬁed. Animal
models are emerging as vital tools to this end, facilitated by the advent of new models and improved understanding of the utility
of existing models. In this paper, we summarize and critically appraise current small and large animal models of CAVD, discuss
the utility of animal models for priority CAVD research areas, and provide recommendations for future animal model studies of
CAVD.
1.Introduction
Valvular heart diseases account for over 23,000 deaths annu-
ally in the United States, with the aortic valve being the most
frequently aﬀected [1]. The aortic valve is composed of three
semilunar cusps or leaﬂets that passively open and close over
25 million times per year to maintain unidirectional blood
ﬂow from the left ventricle to the systemic and coronary cir-
culations. To meet its functional requirements under these
demanding conditions, the thin, pliable leaﬂet tissue is orga-
nized into three distinct layers: (1) the ﬁbrosa on the aortic
side of the leaﬂet, composed primarily of collagen; (2) the
spongiosa in the middle, composed mainly of proteoglycans;
and (3) the ventricularis on the ventricular side, composed
of collagen and elastin [2]. The cellular components of the
aortic valve include a monolayer of valvular endothelial cells
(VECs) on the outer surface of the leaﬂets and valvular
interstitial cells (VICs), which populate each of the three
layers of the leaﬂet. VICs are a heterogeneous population
of mostly ﬁbroblasts [3], a subpopulation of which are
mesenchymal progenitor cells [4]. VICs play the critical role
of remodelling and organizing the valve extracellular matrix
(ECM) to maintain valve integrity [3, 5].
In disease, ECM structure and organization are dis-
turbed, resulting in valve dysfunction. The most common
valvular disease is calciﬁc aortic valve disease (CAVD) [1].
CAVD encompasses early sclerosis, characterized by leaﬂet
thickening without left ventricular outﬂow obstruction, to
late stenosis in which leaﬂets stiﬀen, ﬂow is obstructed,
and cardiac function is compromised. The consequences
of CAVD are signiﬁcant: sclerosis is associated with a
50% increased risk of cardiovascular death and myocardial
infarction [6], and the prognosis for patients with stenosis is
very poor [7]. Because CAVD is a slowly progressing disease
taking several decades to develop, it was once thought to be a
passive “degenerative” or “senile” process. However, CAVD
is now recognized to be an active pathobiological process
that shares many risk factors with atherosclerosis, includ-
ing hypercholesterolemia, smoking, hypertension, diabetes,
chronic renal disease, and male gender [8–10].
Also similar to atherosclerosis, chronic inﬂammation is
a predominant feature of CAVD. This is reﬂected in human
disease by the presence of macrophages and T cells [11–
16]; subendothelial oxidized low-density lipoprotein (LDL)
deposits [11–13, 16, 17]; elevated superoxide and hydrogen
peroxide[18,19];activemastcells[17,20];complementacti-
vation [16]; elevated expression of tumor necrosis factor-α
(TNF-α)[14],matrixmetalloproteinases(MMP-1,-2,-3,-9)
[14, 21], interleukin-2 (IL-2) [22], angiotensin converting
enzyme (ACE), angiotensin II (AngII), angiotensin II type-12 International Journal of Inﬂammation
receptor (AT1R), and chymase [20, 23]; and VEC expression
of intracellular adhesion molecule-1 (ICAM-1), vascular cell
adhesion molecule-1 (VCAM-1) [24, 25], and E-selectin
[25]. Inﬂammatory processes are associated with, and may
drive, the alterations in the valve ECM that are hallmarks
of CAVD, including leaﬂet thickening [13, 14, 21]; collagen
turnover and ﬁbrosis [13, 24, 26]; accumulation of proteo-
glycans and hyaluronan [27, 28]; fragmentation of elastin
[29, 30]; and calciﬁcation [11–13, 15, 17, 22, 24]. Ultimately,
itismaladaptationofthevalveECM(whichisoftenlocalized
totheﬁbrosalayer[11,13])thatresultsinvalvestiﬀeningand
dysfunction.
While many features of human CAVD are well described
(particularly for late-stage disease), speciﬁc pathobiological
mechanisms are not fully understood. Some insight may
come from similarities with atherosclerosis, but less than
40% of patients with CAVD have clinically signiﬁcant coro-
nary atherosclerosis [31], suggesting distinct processes. Thus
there is an unmet scientiﬁc need to determine pathobiolog-
ical mechanisms of CAVD and identify new approaches to
treatCAVD.Animalmodelsareemergingasvitaltoolstothis
end, facilitated by the advent of new models and improved
understanding of the utility of existing models. In this
paper, we summarize and critically appraise current small
and large animal models of CAVD, discuss the utility of
animalmodelsforpriorityCAVDresearchareas,andprovide
recommendations for future animal model studies of CAVD.
2. AnimalModels of CAVD
Animal models are an important platform for studying the
initiation and progression of CAVD in vivo, as well as for
judging the eﬀectiveness of therapeutic interventions. To be
most eﬀective, models should mimic human disease or at
least important facets thereof and the conditions in which
human CAVD develops. The most common species used to
model CAVD are mouse, rabbit, and swine. Of these, only
swine develops CAVD naturally with age, but this process is
slow and is usually accelerated by diet-induced hypercholes-
terolemia. Rabbits are not naturally susceptible to CAVD
butareresponsivetodiet-inducedhypercholesterolemia,and
mice require a genetic predisposition to promote advanced
disease.
2.1. Mouse Models. In the study of CAVD, a large proportion
of contemporary animal work is performed in mouse mod-
els, as mice are uniquely suited to mechanistic studies of
the root causes of aortic valve pathology. Mouse models of
CAVD oﬀer a number of advantages, including their small
size,easyhusbandry,andcosteﬀectiveness.Inaddition,short
generationtime, resultant ease of genetic manipulations, and
availability of clonal samples allow speciﬁc investigation of
key molecular mediators of CAVD [32, 33]. A summary of
the critical elements of mouse models of CAVD is presented
in Table 1.
Despite these advantages, mouse models do suﬀer from
several important limitations. Firstly, the anatomical struc-
ture of mouse aortic valves diﬀers drastically from that of
humans. Mice do not have the trilayer aortic valve tissue
morphology characteristic of human, pig, or rabbit valves;
rather their leaﬂets are usually only ∼5–10 cells thick and
do not exhibit segregated layers [62]. Secondly, and most
importantly, wild-type (WT) mice on standard diets do not
exhibit spontaneous calciﬁcation [32], and consequently the
studyofCAVDinmousemodelsrequiresdietary[34]and/or
genetic [34, 38, 42, 43] or other interventions [46, 47]t o
induce a valvular calcium burden.
Furthermore, the development of atherosclerosis in in-
bred mice is dependent on the background strain in use.
When comparable hyperlipidemia is induced in C57BL/6J
mice, this strain exhibits considerably greater atherosclerotic
lesion formation than the FVBN or C3H strains [63–65].
While strain-speciﬁc susceptibility to CAVD has not been
explored in detail, similarities between atherosclerosis and
valve disease imply that comparable strain-speciﬁc suscep-
tibility to CAVD is present as well. In a related issue, while
theC57BL/6Jmouseisthemostatheropronestrainandmost
commonly used background in mouse models of CAVD,
their valve leaﬂets contain black pigmentation that may
be melanocytes [66] or lipofuscin-containing granules [35].
Regardless of their identity, these dark particulates can ap-
pear in the valve interstitium and are easily mistaken as
positive von-Kossa calciﬁcation staining, thus requiring the
use of alizarin red to accurately determine the extent of
calciﬁcation in C57BL/6J models of CAVD [62].
2.1.1. Diet-Induced and Genetic Mouse Models. As WT
mouse strains do not spontaneously calcify, dietary and/or
genetic insults are often employed. Most commonly, mice
deﬁcient in the low-density lipoprotein (LDL) receptor
(Ldlr−/−)a r eu s e d .Ldlr−/− mice with only apolipopro-
tein B (ApoB)-100 (Ldlr−/−;Apob100-only) spontaneously
d e v e l o pm i l dh y p e r c h o l e s t e r o l e m i a( ∼270mg/dL), dras-
tic reductions in valve oriﬁce diameter (>50%), elevated
transvalvular systolic pressure gradients, and left ventricular
hypertrophy when aged for 17–22 months without dietary
insult [38]. Furthermore, ageing is associated with superox-
ide development indicative of the onset of oxidative stress
and abundant von Kossa staining in the aortic valve [38].
Typically,theHarlanTekladTD.88137,or“Western”diet,
is used in models with a dietary induction component.
This adjusted diet derives 21.2% weight and 42% of
total calories from fat, with 0.2% [36, 42–44, 46]o r
0.25% [39, 40] cholesterol (mouse diet fat content is typ-
ically expressed as percent of total calories from fat).
Towler and colleagues ﬁrst reported extreme hyperlipidemia
(∼1040mg/dL), hyperinsulinemia/hyperglycemia, and min-
eral deposition in Ldlr−/− mice fed TD.88137 for 16
weeks [36]. Ldlr−/− mice fed a similar high-cholesterol diet
(0.15%) develop increases in valve thickness, macrophage
accumulation, superoxide production, activated myoﬁbrob-
lasts and osteoblasts, and mineralization [37]. When mice
are regularly exercised while the high-cholesterol diet is fed,
these pathological symptoms are signiﬁcantly reversed [37].
The Ldlr−/−;Apob
100-only mouse has also been modiﬁed
to incorporate a conditional knockout of the microsomal
triglyceride transfer protein (Mttp) under the control of anInternational Journal of Inﬂammation 3
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inducible Mx1-Cre transgene. Known as the Reversa model,
these Ldlr−/−/Apob
100/100/Mttpﬂ/ﬂ/Mx1-Cre+/+ mice oﬀer
Cre-mediated loss of Mttp activity (required for ApoB li-
poprotein secretion) and allow controllable normalization
of serum cholesterol levels [39]. In conjunction with the
TD.88137 diet, the Reversa mouse develops robust calciﬁc
aortic stenosis. Serum cholesterol rises to 800–1000mg/dL
in 6–12 months, and lipid deposition and macrophage inﬁl-
tration are signiﬁcantly increased. Proﬁbrotic signalling
and myoﬁbroblast activation as measured by pSmad2 and
α-smooth muscle actin (αSMA) are elevated, as is procalciﬁc
signalling (pSmad1/5/8, Msx2, β-catenin, Runx2, osterix)
and superoxide levels, leading to oxidative stress, valvular
mineralization, and positive von Kossa/alizarin red staining
[39, 40]. Importantly, Cre-mediated loss of Mttp activity at
six months (“reversal”) normalizes serum cholesterol levels,
decreases valvular lipid deposition and macrophage inﬁltra-
tion, prevents further calciﬁcation, lowers pSmad2/αSMA,
lowers pSmad1/5/8/Msx2/Runx2, attenuates oxidative stress,
and results in functional improvements in cusp separation
[39]. Interestingly, reversal after 12 months does not lower
pSmad2 or superoxide levels and does not improve leaﬂet
cusp separation distance [40]. The on-demand “switching’’
of cholesterol levels in this model allows, for the ﬁrst time,
regression studies in dietary-induced CAVD independent of
pharmacological intervention.
Diets with substantially elevated cholesterol levels are,
however, not always employed as initiators of mouse CAVD.
One such study employed the use of a high-fat, high-car-
bohydrate diet, where 35.5% of weight and 59% of calo-
ries were derived from fat, but no cholesterol was added
(<0.1% present) [34]. In WT C57BL/6J mice on this diet,
total cholesterol levels are mildly elevated to 166mg/dL,
while Ldlr−/− mice exhibit drastic hypercholesterolemia at
722mg/dL and develop overt diabetes mellitus. Most inter-
estingly, the high-fat, low-cholesterol diet is able to induce
early markers of CAVD even in WT mice: thickened leaﬂets,
black particulates which may be von-Kossa-positive calciﬁ-
cation, decreased aortic valve opening area, and increased
transvalvularbloodvelocitiesarereported,alongwithCD68-
positive macrophage and T-lymphocyte inﬁltration into the
valvular interstitium. These macrophages inﬁltrate primarily
on the high-shear ventricular side of the mouse valve [35].
The development of these disease hallmarks in WT mice
with only mild hypercholesterolemia may prove to be more
relevant to human CAVD.
In addition to the Ldlr−/− model, a second common
genetically manipulated model is the endogenously hyper-
lipidemic [63] ApoE-deﬁcient (Apoe−/−) mouse [41–44, 46,
47]. ApoE allows receptor-mediated removal of very-low
density lipoprotein (VLDL) from the circulation. However,
ApoE also regulates T-cell proliferation and macrophage
function and modulates lipid antigen presentation as well
as general levels of inﬂammation and oxidation [67]. In this
way, deletion of Apoe may signiﬁcantly impact the inﬂam-
matory response to CAVD in a manner distinctly unre-
lated to hypercholesterolemia and/or pathogenesis of the
human disease. This potential for diﬀerential disease
progression remains to be studied in detail. Without dietary
intervention, Apoe−/− mice develop hypercholesterolemia
(∼490mg/dL) [68], and their increasing age up to 2.5
years is correlated with increases in transvalvular velocity,
mild aortic regurgitation, αSMA and osteocalcin (OCN)
expression, macrophage and T-cell inﬁltration, and nodular
calciﬁcation [41]. Administration of the TD.88137 diet to
Apoe−/− mice for 4-5 months induces accelerated early
disease with a substantial increase in serum cholesterol to
∼588mg/dL, thickened leaﬂets, activated endothelial cells,
and subendothelial lesions rich in macrophages (colocalized
with MMP-2/9, cathepsin B, αSMA, ALP, Runx2, and OCN
expression) [42, 43]. Importantly, there is no evidence of von
Kossa or alizarin red staining at this early time point, though
a bisphosphonate-conjugated imaging particle shows signs
of early microcalciﬁcation and colocalizes with cathepsin K
[42, 43]. Another version of the Apoe−/− model includes
coadministration of the adipocytokine leptin, a known
cardiovascular risk factor [44]. Leptin treatment does not
induce hypercholesterolemia nor does atherosclerotic lesion
size change, but von Kossa and ALP-positive staining is
signiﬁcantly increased in leptin-treated Apoe−/− mice, and
osteopontin (OPN) and OCN expression is also increased.
While on a normal diet, oral exposure of Apoe−/− mice
to acrolein, a dietary aldehyde generated during inﬂam-
mation and oxidative stress, induces hypercholesterolemia,
macrophage and lipid inﬁltration, and platelet and endothe-
lial activation [45]. Interestingly, such treatment does not
induceﬁbrosis,nordoesitprovokeasystemicoxidativestress
response.
Along with these two common hyperlipidemic models,
there exist other interesting genetic models that recapitulate
some aspects of CAVD. Knockout of the mineral binding
ECMproteinmatrixGLAprotein(Mgp−/−)pr oduc esspon-
taneous ectopic apatite formation in the arterial collagen
ﬁbrils and von-Kossa-positive calciﬁcation in the aortic valve
[48]. An insuﬃciency of elastin (Eln+/−) produces prolifer-
ation of VICs and aortic regurgitation [50]. Hypomorphic
expression of ﬁbulin-4, an ECM stabilizing protein, results
in thickened leaﬂets, signiﬁcant functional impairments,
and positive pSmad2, pSmad1/5/8, and von Kossa staining
[49]. Mutant tissue displays increased transforming growth
factor-β (TGF-β) and bone morphogenic protein (BMP)
signalling, while an Aﬀymetrix microarray showed diﬀer-
ential expression of a number of immune response genes
between the WT and ﬁbulin-4 deﬁcient animals. Of speciﬁc
interest to the role of inﬂammation in spurring the onset of
CAVD are mice deﬁcient in the antiinﬂammatory cytokine
interleukin-1 receptor antagonist (Il1rn−/−). These animals
develop thickened aortic valves inﬁltrated by macrophages
and containing diﬀerentiated myoﬁbroblasts, while aged
Il1rn−/− mice develop calciﬁed lesions with functional
impacts on transvalvular blood velocity [60]. Circulating
levels of TNF-α rise dramatically in this model, and the
importance of this chemokine to CAVD pathogenesis is
underscored by double knockout TNF-α−/−;Il1rn−/− mice
which do not develop CAVD [60].International Journal of Inﬂammation 5
2.1.2. Congenital and Developmental Mouse Models. The
presence of a congenital bicuspid aortic valve is associated
with drastically increased risk of CAVD [69]. Mutations in
the transcriptional regulator NOTCH1 have been shown to
cause bicuspid valves and CAVD development in humans.
ThenormallydevelopingmousevalvedisplayshigherNotch1
levels than during postnatal growth [70]. Mice heterozygous
for Notch1 (Notch1+/−) fed a Western diet with 0.2%
cholesterol for 10 months exhibit ﬁvefold greater aortic
valve calciﬁcation than WT controls, but do not exhibit
bicuspid valves [51]. Recently, mice haploinsuﬃcient for the
primary nuclear Notch eﬀector protein recombining binding
protein suppressor of hairless (RBPJK) were challenged with
a high-cholesterol/cholate diet for a shorter 4-month period
[52]. These mice present normal trileaﬂet aortic valves, and
develop thickened and calciﬁed leaﬂets, macrophage inﬁl-
tration, collagen deposition, and proﬁbrotic/osteogenic sig-
nalling. Interestingly, Notch1+/− mice display relatively
little functional impairment when compared to RBPJk+/−
mice, implying that other Notch eﬀectors contribute to
valvular homeostasis [52]. Periostin is highly expressed in
the endocardial cushion during embryogenesis, and its de-
letion (Postn−/−) induces overexpression of delta-like
1h o m o l o g( Dlk1), a negative regulator of Notch1 [53]. By 10
months of age, the valves of Postn−/− mice exhibit a severely
deformed bicuspid-like morphology displaying expression
of Runx2, OPN, and OCN, along with signiﬁcant valvular
calciﬁcation (von Kossa). Paradoxically, when Postn−/−
mice are fed a high-fat diet for four months, they display
decreased valve thickness, macrophage inﬁltration, myoﬁ-
broblast diﬀerentiation, annular ﬁbrosis, and MMP-2/13
expression when compared with WT mice fed the same
diet, possibly reﬂecting a reduced ability of myoﬁbroblasts
and macrophages to adhere to and inﬁltrate the ECM
[54]. Periostin expression is mutually exclusive to that of
chondromodulin-I (ChmI), an antiangiogenic factor. Aged
ChmI−/− mice display increases in valve thickness, lipid
deposition, calciﬁcation, VEGF-A, and angiogenesis [55]. In
humans, expression of endothelial nitric oxide synthase
(eNOS) in the valvular endothelium is drastically reduced
in bicuspid valves [71], and mice lacking eNOS (Nos3−/−)
display a high incidence (∼50%) of bicuspid aortic valve
[56]. The susceptibility of this mouse model to CAVD and
inﬂammatoryprocessesisasofyetunexplored.Paradoxically
however, Nos3−/− mice do not develop atherosclerosis when
fed a high-cholesterol atherogenic diet [72], a phenomenon
which may be the result of reductions in eNOS-driven LDL
oxidation in the vasculature [73].
Signalling pathways normally associated with embryonic
development of the valve have recently been implicated in
CAVD pathogenesis, and have become the focus of several
mouse models of the disease [5]. While epidermal growth
factor receptor (EGFR) has been implicated in the devel-
opment of cancer, and targeted for inhibition by cancer
therapeutics, mice carrying a hypomorphic allele of Egfr
(Egfrwa2/wa2) exhibit congenitally enlarged valves, and mature
mice display valvular OPN expression, macrophage inﬁl-
tration, and extensive von Kossa-positive calciﬁcation [59].
Interestingly, these results imply that cancer patients with
congenital valve defects or other cardiovascular risk factors
should avoid EGFR inhibition. The Smad6 inhibitory pro-
tein regulates TGF-β signalling and mediates endocardial
cushion transformation, and mutation of the Smad6 gene
(Madh6−/−) in mice produces valvular hyperplasia, outﬂow
tract septation defects, elevated blood pressure, and aortic
ossiﬁcation [57]. Endocardial cushion development is also
promoted by the Twist1 transcription factor and is upreg-
ulated in human CAVD. Mice engineered with persistent
Twist1 (CAG-CAT-Twist1;Tie2Cre mice) develop two- to
threefold increases in area, length, and thickness of the
aortic valve [58]. Expression of collagen-II, periostin, and
the matrix remodelling enzymes MMP-2/13 are also elevated
[58].
2.2. Rabbit Models. In CAVD research, rabbits are the most
common large animal model used. Rabbits are desirable for
a number of reasons as they (1) have a trilayer valvular mor-
phology [74]; (2) respond to dietary cholesterol [74–86]; (3)
arerelativeeasytomanageduetotheirmediumsize;(4)have
some similarities to human lipoprotein metabolism [87–89];
(5) are susceptible to accelerated calciﬁcation with vitamin
D2 (VitD2) [80, 82]; (6) are available as transgenic [90–92]
and natural mutant strains [93, 94].
On the other hand, there are a number of dissimilarities
with human disease. Rabbits do not form spontaneous ath-
erosclerotic lesions and therefore require very high choles-
terol levels to induce more advanced disease [78–80, 84, 85],
unless very long-term studies [74, 83, 86] or VitD2 supple-
mentation [80, 82] are used. Rabbits also have signiﬁcant
diﬀerences in their lipid metabolism from humans [87–89],
which can result in their development of cholesterol storage
syndrome while on high-cholesterol diets (0.5–3%), with
cholesterol deposited in regions such as the liver, adrenal
cortex, and reticuloendothelial and genitourinary systems.
Rabbits have also been reported to form atherosclerotic
lesions that do not resemble those in humans [74,88, 102]. A
summary of the critical elements of rabbit models of CAVD
is presented in Table 2.
2.2.1. Diet-Induced Rabbit Models. The standard rabbit
model is the New Zealand white rabbit (NZWR) with a start-
ing weight of 1.6–3kg [74, 76–86] and hypercholesterolemia
inducedbyoneoffourmaindietcategories(1)moderate-to-
high cholesterol with [75–77, 81] or without fat [78, 79, 84,
85, 95, 103]; (2) moderate cholesterol and VitD2 [19, 80, 82];
(3) low cholesterol [74, 83, 86]; or (4) VitD2 only [82, 98].
(Below, rabbit diet additions are expressed as additional
weight percentage added.)
Moderate-to-high cholesterol diets (0.5–2%) induce very
high total blood cholesterol levels, ranging from approxi-
mately 1000–3500mg/dL [79, 80, 84, 85], and sometimes
induce extreme hypertriglyceridemia [79]. After one week
on this diet, lipids inﬁltrate into the subendothelial region of
the ﬁbrosa prior to macrophage presence [75] and associate
with collagen ﬁbres and the proteoglycans that connect them
[76, 81]. This is paralleled by hyperplasia of the basal lamina,
including fragmentation of the elastin and collagen bundles,
and accumulation of proteoglycan in the ﬁbrosa [75], with6 International Journal of Inﬂammation
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both VECs and VICs increasing their protein production.
By eight weeks there is macrophage inﬁltration, myoﬁbrob-
last presence, and increased proliferation, ACE, OPN, and
osteoblast gene expression (alkaline phosphatase, OPN,a n d
Runx2)[ 78, 95]. Highly sensitive C reactive protein (hsCRP)
in the blood is also increased, indicating an inﬂammatory
state [78], and there is impaired endothelial integrity on the
aortic side with decreased eNOS expression [95]. Foam cells
and lipid uptake by VICs have also been seen prior to 12
weeks [75]. By 12 weeks, some calciﬁcation is present [85],
and there is a slight increase in apoptosis of macrophages
and proliferating ﬁbroblasts (0.1% of cells) [79]. With the
addition of VitD2 to 0.5–1% cholesterol diets, by 10–12
weeks there is enough calciﬁcation and thickening to cause
decreased aortic valve opening area [19, 80, 82] and aortic
Doppler velocity index [97], and increased transvalvular
velocities [80, 82, 97] and echogenicity [19]. There are also
macrophages present in the subendothelial spaces [19, 82,
97], and T cells [82] and smooth muscle actin positive
cells found near the calciﬁcation [82, 97]. These valves
are thickened due to increased collagen, cellular inﬁltrates,
calciﬁcation[19, 97], and lipid deposition [97] in the ﬁbrosa,
with increased expression of OPN and Runx2, and the
presence of osteoclasts. Reactive oxygen species (ROS) are
also present around calciﬁed areas (superoxides, hydrogen
peroxide, indicators of nitro/oxidative stress and NAD(P)H
oxidative subunits) [19], as well as tissue factor [97].
Low-cholesterol diets (0.125–0.25% cholesterol) main-
tain more moderate cholesterol levels of around 500–
800mg/dL [74, 83, 86]. By ﬁve months, lipid deposition and
collagen disarray are seen in the ﬁbrosa, with macrophages
and OPN in the lesion. By 10–15 months there is an increase
in macrophages, OPN, collagen area, thickness, and lipid
deposition. However, no calciﬁcation is seen [74, 83]
until 30 months, which is accompanied by an increase
in macrophages, T cells, and collagen deposition, and the
presence of regurgitant ﬂow [83].
VitD2-only treatment has been used in some models to
induce advanced CAVD [82, 98]. By 8–10 weeks, functional
changes indicative of mild stenosis including increased
peak transvalvular velocity and pressure gradients, increased
echogenicity of the valve [82, 98], and decreased aortic valve
area [98] occur. Histologically, these valves display increased
burden of lipids, leukocytes, macrophages [98], myoﬁbrob-
lasts, T cells [82], and calciﬁcation [82, 98]. Serum levels
of cholesterol, calcium, phosphate, creatinine [98], and
calcium-phosphate product [82] were also seen to increase.
There is also the indication that VitD2 might increase the
oxidative stress (increased thioredoxin-interacting protein)
and impair VEC function (increased plasma asymmetric
dimethylarginine, an NO inhibitor) [98]. This indicates
that VitD2 alone is capable of inducing CAVD resulting in
functional impairment of the valve [98]. However, use of
a hypercholesterolemic diet in combination with VitD2 at 12
weeks produces greater valvular functional impairment than
VitD2 alone [82].
2.2.2. Genetic Rabbit Models. Rabbit models utilizing spon-
taneous mutations as well as transgenic manipulations are
available. These models primarily have alterations in the
LDLR and/or apolipoproteins that result in hypercholes-
terolemia when on a cholesterol-free, limited fat diet.
Such models include (1) Watanabe heritable hyperlipidemic
(WHHL) rabbits, which have a spontaneous LDLR mutation
[84, 93, 104, 105]; (2) St. Thomas Hospital rabbits, which
acquire hypertriglyceridemia as well as hypercholesterolemia
[94]; (3) rabbits with altered lipid proﬁles, such as induced
human ApoB100 [90, 94]o rA p o ( a )[ 91]. Of these, only the
WHHLrabbithasbeenusedinastudyofCAVDtoshowthat
hypercholesterolemia-inducedcalciﬁcationmaybemediated
in part by the LPR5/β-catenin pathway [84]. Comprehensive
reviews of genetically altered models of rabbit atherosclerosis
have been done by Brousseau and Hoeg [87] and Fan and
Watanabe [92].
2.3. Porcine Models. Porcine models are regarded as excellent
animals for atherosclerosis research [88, 89, 106–108]a n d
more recently for the study of CAVD [32]. Swine have many
similarities to humans, including similar systemic hemody-
namic variables and heart anatomy [89], including trilayered
aortic valve leaﬂets. They also have similar lipid proﬁles [61]
and lipoprotein metabolism [106, 108] to humans, though
their high-density lipoprotein (HDL) level does rise with hy-
percholesterolemic diets. The porcine genome is of a com-
parable size to that of humans and is homologous in both
sequence and chromosomal structure [32]. Swine naturally
develop atherosclerotic lesions, which are accelerated by
high-cholesterol/high-fat diets and result in human-type
lesions [108–111]. The size of swine also makes them ideal
forstudiesthatcharacterizeleaﬂetmechanicalpropertiesand
for studies requiring blood analysis.
Size is also the primary limitation of swine, as there is
increased complexity and expense in maintaining them. In
many cases, this has led to the use of mini- [106, 112, 113]
and micro- [114] swine breeds for atherosclerosis studies,
instead of full sized Yorkshire swine. Standard weights at six
months are around 33kg for Yucatan mini, 24kg for Sinclair
mini, and 20kg for Yucatan microswine. These are signiﬁ-
cantly smaller than Yorkshire swine (approximately 115kg
at six months). Smaller breeds also develop human-type
atherosclerosislesionsrangingfromearly(3-4months)[106,
113] to advanced lesion (8 months) with a necrotic core,
ﬁbrous cap, haemorrhage, calciﬁcation, and medial thinning
[112]. They may also be very good models for CAVD
investigations, but have not been used for this purpose to
date. A summary of the critical elements of porcine models
of CAVD is presented in Table 2.
2.3.1. Diet-Induced Porcine Models. Though porcine models
have been principally used in atherosclerosis research, they
have recently been employed to study CAVD. Typical hyperc-
holesterolemicswinedietsconsistofastandardcorn/soybean
diet with an additional 1.5–2% cholesterol and 10–20%
fat, sometimes with 0.7–1.5% sodium cholate (porcine diet
additions are expressed as additional weight percentage
added). There is some indication that diets started prior to
sexualmaturitymaybemoreeﬀectiveatproducingadvanced
disease [108]. Standard lipid proﬁles for studies ranging8 International Journal of Inﬂammation
from 2 weeks to 12 months in length show total cholesterol
of ∼300–500mg/dL (2- to 8-fold increase), LDL ∼200–
500mg/dL (4- to 11-fold increase), HDL increases of 1.5-
to 4-fold, and heterogeneous triglyceride (TG) levels ranging
from twofold increase to twofold decrease.
Initial CAVD studies show evidence that swine on hyper-
cholesterolemic diets develop human-type disease. Macro-
scopic focal areas of increased opacity are seen by six months
on a hypercholesterolemic diet with [100] or without dia-
betes [101]. Small early calciﬁc nodules are also seen his-
tologically at 6-7 months of age either with diet for two
weeks or six-months [101] and with six month diet and
diabetes [100]. Subendothelial lipid inﬁltration is seen only
within the ﬁbrosa layer, increasing with diet duration [100,
101]; however there is no frank inﬂammation seen after two
weeks or six months of diet [101]. In normal valves it has
been found that the VECs on the aortic side of the valve
have an antioxidative, noninﬂammatory, and calciﬁcation
permissive phenotype [100]. After treatment with a hyper-
cholesterolemic diet, the aortic VECs display a protective
phenotype described as antiinﬂammatory, antiapoptotic,
and anticalciﬁc [101]. Notably, VECs on the aortic side are
more responsive to the diet. More investigation is needed
to explain the mechanistic foundations of side-speciﬁc VEC
phenotypes.
Atherosclerotic swine exhibit a standard human-type in-
ﬂammatory response in the vasculature [108], so it is notable
that the same is not observed in the valve. However, early
human CAVD often does not have many inﬂammatory
cells present [11]. In leaﬂets with mild disease changes,
macrophages were only found in 20% of the lesions and
T cells in 55% [13], with greater amounts appearing in
stenotic valves [12, 13, 15], ranging from 59% [15], to 75%
[13] of valves analyzed.
2.3.2.GeneticPorcineModels. Naturallyoccurringmutations
have also been exploited in swine to develop models of
nondiet-induced hypercholesterolemia for atherosclerosis
research;theymayalsobesuitableasmodelsofCAVD.These
models have mutations in the LDLR and/or apolipopro-
tein genes. Some common models include (1) inher-
itedhyper-low-densitylipoproteinandhypercholesterolemia
(∼250mg/dL) from mutant alleles Lpb5, Lpr1,a n dLpu1
for ApoB and ApoU with normal LDLR [115, 116]; (2)
familial hypercholesterolemia (130–490mg/dL) due to an
LDLR mutation with altered lipid proﬁles [117, 118]; or
(3) familial hypercholesterolemia due to mutations relating
to ApoB and LDLR (<300mg/dL) [119] .T h e s em o d e l sa r e
capable of achieving complex atherosclerotic lesions by two
to three years of age without diet induction [115].
2.4. Other Animal Models. Many other animals have been
used historically or in certain niche areas as models of
atherosclerosis. They include rats, hamsters, pigeons, guinea
pigs, cats, dogs, or nonhuman primates and have been
reviewed by Moghadasian et al. [88, 107]. Occasionally these
animals have been used for CAVD studies [75, 120, 121]a n d
some may be suitable for studying certain comorbidities that
directly relate to CAVD [122, 123]. However, they are not
standard models for CAVD currently.
3. EmergingCAVD Research Themes and
the Role of AnimalModels
Increased appreciation and understanding of CAVD as an
active, cell-mediated process has renewed interest in valve
(patho)biology and the possibility for therapeutic inter-
vention. To this end, priority research areas were recently
identiﬁed by the National Heart and Lung and Blood
Institute Aortic Stenosis Working Group [124] and include
(1) improving understanding of the basic biology of CAVD,
including signalling pathways and the roles of inﬂammation
and biomechanics in disease initiation and progression;
(2) determining the unique contributions of comorbidities
to disease development; (3) developing highly sensitive
imaging modalities to identify early and subclinical CAVD;
(4) determining the feasibility of earlier pharmacological
intervention. Research in each of these areas currently
beneﬁts from animal models and will continue to require the
use of appropriate models in the future, as discussed below.
3.1. Basic Biology of CAVD. The biology of CAVD is com-
plex, involving multiple cellular and molecular regulators,
genetic and environmental cues, and interacting signalling
cascades [125]. Clearly animal models, notably transgenic
mice, are important for dissecting speciﬁc signalling path-
ways and their functional consequences; this topic was
recently reviewed [126]. Here we highlight inﬂammation
and biomechanics as two factors that are associated with
CAVD and likely inﬂuence signalling pathways, but have not
been well studied. Animal models are well suited to study
inﬂammation and biomechanics and thus will be critical
t o o l st ot h i se n d .
3.1.1.Inﬂammation. DespitethestrongassociationofCAVD
with inﬂammation, the eﬀects of inﬂammatory cytokines
andrelatedfactorsonvalvepathobiologyhavenotbeenthor-
oughly studied. Many animal models of CAVD demonstrate
inﬂammation and may therefore be well suited to dissecting
the role of inﬂammation in CAVD pathogenesis. Evidence
of inﬂammation in mice includes signiﬁcant macrophage
[34, 37, 39, 41–43, 46, 47, 59]a n dT - c e l l[ 34, 41] inﬁltration
in some models. Others have seen increased expression of
immuneresponse genes[49],MMPs[43,58],andcathepsins
[42, 43, 46]. Lastly, oxidative stress as measured by superox-
ide production has been exhibited in a number of models
[37–40]. In rabbits, macrophages [74, 75, 77–79, 82, 83, 95],
foam cells [75, 79], T cells [82, 83], and increased MMP-3
expression [103] are reported in valves along with increased
hsCRP levels in the blood [78, 85]. In porcine leaﬂets,
VECs on the disease-prone aortic surface progress from a
noninﬂammatory phenotype in normal valves [100]t oa n
antiinﬂammatory and antiapoptotic phenotype with early
disease [101].
While inﬂammation has been clearly demonstrated in
both animal and human histopathological data, studies areInternational Journal of Inﬂammation 9
typically limited to characterization of the inﬂammatory
response and not the mechanistic causes. Mouse models of
CAVD are well suited for studying pathological mechanisms,
as conditional knockouts and other genetic manipulations
in this species are relatively straightforward. The Il1rn−/−
mouse exempliﬁes this approach, as studies with this model
have demonstrated a protective role for the interleukin-
1 receptor antagonist in preventing CAVD onset [60].
However, the lack of a trilayer leaﬂet morphology in mice
diﬀers from that of the human, rabbit, and swine and may
impacttherelevanceofﬁndingsinmicetohumandisease.In
addition, care must be taken when employing the common
Apoe−/− mouse model to speciﬁcally study inﬂammatory
CAVD mechanisms, as recent work has implicated ApoE
as a regulator of inﬂammation [67]. Rabbit and porcine
valves have three layers and are large enough to allow
study of biomechanical forces and their impact on valvular
inﬂammation. For example, altered ﬂuid ﬂow-induced shear
stress induces endothelial expression of VCAM-1, ICAM-1,
BMP-4, and TGF-β1[ 127] and elevated mechanical stretch
upregulates MMP and cathepsin activity in porcine leaﬂets
ex vivo [128].
Future animal studies will need to better characterize
inﬂammatory processes at various stages of disease develop-
ment and begin to dissect the regulatory mechanisms that
link inﬂammation to ECM remodelling and valve dysfunc-
tion. The validity and utility of various animal models to
study inﬂammation in CAVD will be further clariﬁed by
improved temporal resolution of the pathogenesis of human
valvular disease.
3.1.2. Biomechanics. The aortic valve exists in a highly dy-
namic mechanical environment where it is exposed to sig-
niﬁcant blood ﬂow-induced shear stresses, pressure loads,
ﬂexural deformations, and mechanical resistance from the
ECM. Each of these mechanical stimuli regulates valve cell
biology and therefore likely contributes to both homeostasis
and disease [129, 130]. However, much of what is known
about mechanoregulation of valve biology is based on in
vitro or ex vivo studies and the use of normal, nondiseased
tissue sources. Animal models are an important, but largely
unexploited source of diseased tissue for ex vivo and in vivo
studiesofvalvebiomechanicsandmechanobiologyinCAVD.
To date, the mechanical properties of normal porcine
valves have been extensively characterized at multiple length
scales: whole leaﬂets [131–137], individual layers [138, 139],
orathigherspatialresolution,focalregionswithinindividual
layers [140]. Normal porcine aortic valves have also been
used to study the eﬀects of aberrant mechanical forces on
valvepathobiologyexvivo[127,128,131,136,141–143].The
similarity of the trilayer structure, size, and anatomy of the
porcine valve to human valve makes them excellent models
for structural and biomechanical studies.
Todate,themechanicalpropertiesofdiseasedaorticvalve
tissue from humans, swine, or other species have not been
reported, likely due in part to the limited availability of tissue
samples and lack of well-characterized large animal models
of CAVD. Such information is critical to deﬁning the role of
ECM mechanics in disease regulation [144] and should be
a focus of future research. The suitability of porcine valves
for biomechanical testing lends promise to the use of porcine
CAVD models for the study of biomechanical changes with
disease progression. Rabbit models may also be suitable, but
their smaller size in comparison to porcine valves makes
them less desirable. Mouse valves lack the trilayer human-
like leaﬂet morphology and are diﬃcult to test mechanically
due to their small size (∼500μml o n ga n d5 0 μm thick)
[62]. However, the speed at which advanced disease can be
obtained in mice and the feasibility of studying the eﬀect of
genetic knockouts on valve mechanics do provide signiﬁcant
beneﬁt. To do this end, micromechanical test methods, like
micropipette aspiration (MA), have been adapted recently to
characterize mouse leaﬂet properties [145]. MA also shows
promise for its ability to measure focal, microscale tissue
properties. Recently, this technique was used to demonstrate
that there is signiﬁcant spatial heterogeneity in the local
elastic modulus within individual layers of normal intact
porcine aortic valves, but that on average, the ﬁbrosa layer is
stiﬀerthantheventricularislayer,withdistinctlystiﬀandsoft
regions in the ﬁbrosa and ventricularis, respectively [140].
The use of MA with animal models of CAVD promises to
enable high spatial resolution biomechanical testing that is
able to address the focal nature of CAVD.
Ultimately, the gap between in vitro/ex vivo biomechan-
ics studies and human disease will need to be bridged by in
vivo biomechanical models of CAVD. The valvular mechan-
ical environment and forces experienced by valve cells are
deﬁned in part by the external hemodynamic forces that
shear and deform the valve leaﬂets throughout the cardiac
cycle.Manipulation oftheseforcestotest directcausaleﬀects
of mechanics on valve biology is challenging because of
confounding factors that result from invasive manipulation
of the valve or perivalvular tissues (e.g., hypertension). As
a result, the causal eﬀects of hemodynamic forces on CAVD
haveyettobe investigated in vivo.Some advancesin thisarea
have been made in the study of the eﬀects of hemodynamics
on valve development, which were elegantly studied in the
zebraﬁsh by using microbeads to impair blood ﬂow [146]. It
isbelievedthataspectsofadultvalvediseasemayrecapitulate
developmental processes [147], and therefore the zebraﬁsh
and other developmental models may in fact have some
utility for studying the link between hemodynamics and
adult valve biology in vivo.
3.2. Contributions of Comorbidities to CAVD. CAVD often
coexists with other conditions, including hypercholes-
terolemia, diabetes mellitus, chronic renal disease, hyperten-
sion, metabolic syndrome, and disorders of calcium or phos-
phate metabolism [148–150]. It is likely that these comor-
bidities uniquely contribute to the initiation and/or progres-
sion of CAVD [124]. A variety of animal models have been
used to investigate comorbidities and CAVD, most coupled
with a diet that induces hypercholesterolemia to accelerate
disease.
A frequently studied comorbidity is familial hyperc-
holesterolemia, an inherited form of hypercholesterolemia
that can be caused in humans by more than 800 diﬀerent
mutations [151]. Familial hypercholesterolemic models do10 International Journal of Inﬂammation
not require diet induction to induce and accelerate disease,
and provide a medium for deeper investigation into speciﬁc
elementsofthedisease,especiallylipoproteinmetabolism.In
mice, the Apoe−/− and Ldlr−/−;Apob
100-only models con-
tain mutations which mimic familial hypercholesterolemia
[38, 41]. As discussed in earlier sections, the WHHL rabbit
[84, 93, 104, 105], the St. Thomas Hospital rabbit [94],
and a number of porcine models [115–119] also mimic
familial hypercholesterolemia. Of these, only the Apoe−/−
andLdlr−/−;Apob
100-onlymicemodels[38,41]andWHHL
rabbit [84] have been used to study CAVD to date.
The impact of a variety of other comorbidities on
vascular disease has been studied in various species in
whichhypercholesterolemiawasinducedbydiet.Theunique
imbalances caused by diseases such as diabetes, chronic
renal disease, hypertension, metabolic syndrome, and high
serum minerals likely also inﬂuence CAVD progression and
could lead to necessary unique insights into disease pathways
and inciting factors. To date, however, these models have
only been applied to study CAVD in mice. For example,
the Apoe−/− mouse model has been combined with sur-
gically induced chronic renal disease (CRD) to recapitulate
the accelerated CAVD which accompanies human CRD
[152]. This 5/6 surgical nephrectomy model with normal
diet induces serum hypercholesterolemia after six months
(∼400mg/dL), as well as prototypically high serum phos-
phate, creatinine, and cystatin C levels. Valve leaﬂets stain
strongly for microcalciﬁcation and macrophages, as detected
by near-infrared imaging of targeted nanoparticles [47]. The
Apoe−/−;5/6 nephrectomy model has also been combined
with the TD.88137 diet and a knockout of the elastolytic
proteinase cathepsin S (Ctss−/−). Knockout of cathepsin
S reduced valvular calciﬁcation, macrophage accumulation,
osteogenic and elastolytic activity, and elastin fragmentation
[46]. Metabolic syndrome has been recapitulated in WT
C57BL/6J mice with the use of a high-fat, high-carbohydrate
diet which includes no added cholesterol and produces mild
hypercholesterolemia [34], while exercise has been shown to
mitigate the eﬀects of the TD.88137 diet in Ldlr−/− mice
[37]. The development of diabetes is common in many
mouse models of aortic valve disease [34, 39], but it is
typically a side eﬀect of the studied insult and rarely
investigated as a primary initiator of disease [36].
CAVD comorbidities have not been studied in other spe-
cies, although appropriate putative models do exist. For
example, rabbit comorbidity models include diabetes [153],
hypertension [154], metabolic syndrome [155, 156], and
high serum calcium [80, 82], along with hypercholes-
terolemia. Porcine models have also combined diabetes
[106,108,110–112]orhypertension[157]withdiet-induced
hypercholesterolemia. All of these models have been applied
to study atherosclerosis, and presumably would be appropri-
ate and eﬀective for studying CAVD, perhaps oﬀering some
advantages over murine models.
3.3. Development of Sensitive Imaging Modalities for Early
CAVD Detection. The ability to arrest or slow CAVD pro-
gression will likely require early disease detection, before
signiﬁcant calcium burden and hemodynamic dysfunction
have occurred. For this reason, there is signiﬁcant inter-
est in developing sensitive imaging modalities for early
stage detection. Targeted ﬂuorescent nanoparticles are one
promising strategy. Commercially available nanoparticles
speciﬁcally targeting cathepsin S, cathepsin K, cathepsin
B, macrophages, VCAM-1, MMP-2/9, and hydroxyapatite
have been imaged with intravital dual channel ﬂuorescence
imaging in a number of animal studies of CAVD [42, 43,
46, 47]. These or other molecular imaging techniques are
promising approaches to detect early human CAVD, and
clearly preclinical animal models will be critical to their
validation.
Beyond their application in clinical medicine, sensitive
noninvasive imaging methods are also important for animal
studies, as they enable tracking of disease progression and
measurement of cardiac function in vivo over the duration
of an experiment. Due to their relatively large size, imaging
of rabbits and pigs is typically performed with clinical
machines [80, 82, 114]. A possible future trend is to combine
nanoparticles with standard imaging modalities for targeted
detection. For example, iron oxide (MION-47) and MRI
imaging were used to detect early CAVD lesions in rabbits
fedalow-cholesteroldietbytargetinginvadingmacrophages.
However, in these experiments, the MION-47 was also taken
up by myoﬁbroblasts in control and cholesterol-fed animals,
and therefore more speciﬁc targeting may be needed [86].
Manymousestudiescontinuetoemployclinicalechocar-
diography using frequency ranges of ∼10–15MHz to non-
invasively examine the functional state of the mouse aortic
valve [34, 37–41, 49]. Measurements such as transvalvular
blood ﬂow velocity, valve opening time, cusp separation dis-
tance, and valve opening area are routinely performed. How-
ever, due to the high heart rate of an adult mouse, these
frequency ranges only capture 10–20 frames per cardiac
cycle [158]. More recently, a high-frequency ultrasound
system better suited to imaging the mouse heart has been
developed [159]. This system operates at 20–40MHz, oﬀers
a ∼fourfold higher spatial resolution and ∼twofold higher
temporal resolution than clinical echo machines [160]a n d
has been validated by magnetic resonance imaging (MRI)
as an accurate means to image functional and anatomical
parameters of the mouse heart [161]. Increasingly, investi-
gators are taking advantage of this improved technology to
delve into the impacts on cardiac function in mouse models
of CAVD [50, 53, 59]. Of note, however, is that the higher
frequency range of this technique impairs penetration depth
and can cause diﬃculties in successfully imaging aged and
obese mice. An alternative is to use high-strength (5–15T)
MRI to image mouse cardiac valves directly [39, 43].
3.4. Evaluation of Pharmacological Interventions. Currently,
there is no medical treatment for CAVD, and clinical trials
have yielded mixed, but generally discouraging, results that
motivate the identiﬁcation and development of new phar-
macological interventions to slow or stop the calciﬁc process
in CAVD [162]. Clearly, animal models of CAVD are and
will continue to be essential to evaluating therapeutics. As
is clear from the summary below, the eﬃcacy of various
pharmacological interventions depends largely on the stageInternational Journal of Inﬂammation 11
of the disease at the time of drug administration. Thus,
translation of results from animal models to humans will
be challenging (as CAVD is intentionally accelerated in most
models), but must remain a priority.
3.4.1. HMG-CoA Reductase Inhibitors. HMG-CoA reductase
inhibitors (statins) were one of the ﬁrst class of drugs to be
directly tested for the treatment of CAVD, with mixed results
in both clinical studies [163–166]a n dN Z Wr a b b i tm o d e l s
[78, 83, 85]. In the rabbit studies, statins were administered
either concomitant with diet initiation [78, 85] or 15 months
after diet initiation, by which point there was established
sclerosis but no calciﬁcation or functional abnormalities
[83]. In the former case, eight weeks of simultaneous athero-
genic diet and statin treatment resulted in decreased total
cholesterol, leaﬂet thickness, OPN, macrophage inﬁltration,
cell proliferation, and Runx2 expression compared with
diet-only samples [78]. However, the high-cholesterol diet
used in this study induced lesions throughout the leaﬂet,
which does not mimic the ﬁbrosa speciﬁcity of human
disease. In a subsequent study using a lower cholesterol
diet, three months of statin treatment (initiated at the same
time as dietary insult) decreased the amount of calciﬁcation
and increased eNOS expression [85]. In WHHL rabbits,
atorvastatin attenuated hypercholesterolemia-induced cal-
ciﬁcation when administered concomitantly with diet, in
part through the LDLR LRP5/β-catenin pathway [84]. In
contrast, when statins were administered for 15 months
after disease had already been established in NZW rabbits,
treatment decreased inﬂammatory cell inﬁltration and OPN
expression but did not prevent calciﬁcation or collagen
deposition, reduce lipid burden, or prevent the functional
impairment that occurred without statin treatment [83].
Statins have not been extensively tested in mouse models
of CAVD, though preliminary studies with pitavastatin in
Il1rn−/− m i c ea r er e p o r t e dt oh a v en ot h e r a p e u t i cb e n e ﬁ t
[60]. However, aggressive lipid lowering has been more
directly achieved with the Reversa mouse model, which
signiﬁcantly normalizes plasma cholesterol levels with the
u s eo fag e n e t i cs wi t c h( ∼800 →∼200mg/dL) [39, 40]. Early
intervention after six months on the TD.88137 diet was able
to reverse nearly all pathological signs of CAVD, but reversal
at 12 months after signiﬁcant calcium burden had already
developed did not produce measureable improvements in
aortic valve function.
In total, preclinical and clinical trials to date do not
support statin therapy as a primary treatment for patients
with valvular heart disease to slow its progression [124].
The inconsistent results among the clinical trials likely reﬂect
many diﬀerences, including enrolment criteria and timing
of therapy [124], which are reﬂected in the animal studies
by the extent of disease at the time of treatment. Thus,
it is important that animal models mimic the progression
and severity of human disease and experimental designs
match the clinical situation as closely as possible, so that
preclinical data can be translated to inform the design and
interpretation of future clinical trials of statins or other
pharmacological interventions.
3.4.2. Renin-Angiotensin-Aldosterone System Inhibitors. The
renin-angiotensin-aldosterone system (RAAS) controls
blood pressure and ﬂuid and electrolyte balances, and
members of this family may have roles in normal phys-
iological repair of the valve. Dysregulation of RAAS
components can have proatherothrombotic eﬀects resulting
in pathologic ﬁbrosis and calciﬁcation of the aortic valve
[167]. The major members of this family implicated in
CAVD are ACE, AngII, and AT1R [20, 23]. Aldosterone
receptors have also been shown to be present in rabbit aortic
valves [96]. AngII, produced by ACE and mediated by the
AT1R, may contribute to CAVD by promoting macrophage
lipid accumulation and inﬂammation, increasing oxidative
stress, impairing ﬁbrinolysis, and stimulating production
of the proteoglycan biglycan, which can retain lipoproteins
[125].
ACE inhibitors, angiotensin receptor blockers (ARBs),
and aldosterone receptor antagonists (ARAs) have begun to
be investigated for treatment of CAVD. ACE inhibitors have
shown mixed results in retrospective clinical studies with
one showing a strong association between the use of ACE
inhibitors and decreased valve calciﬁcation [168] and the
other ﬁnding no eﬀects [169]. In NZWR, treatment with
the ACE inhibitor ramipril concomitantly with induction
of CAVD by VitD2 at 25000IU (four days per week) for
eight weeks retarded the development of CAVD [99]. The
ARB olmesartan decreased macrophage and myoﬁbroblast
accumulation, decreased OPN, ACE,a n dRunx2 mRNA
expression, and maintained endothelial integrity when
administered to NZWR during the last four weeks of an
eight-week 1% cholesterol diet treatment [95]. The ARA
eplerenone showed no eﬀect in clinical trials of moderate- to
severestenosis [170]. However, administration of eplerenone
to NZWR for the last four weeks of an eight-week 1%
cholesterol diet elevated aldosterone levels without altering
blood pressure and decreased macrophage accumulation,
ACE expression, and calciﬁcation within the leaﬂets [96].
3.4.3. Antioxidants. Reactive oxygen species are present in
both human [20, 23] and rabbit [19] valves during CAVD.
The antioxidative compounds tempol and lipoic acid (LA)
were tested individually by concomitant administration with
a CAVD-inducing diet of 0.5% cholesterol and VitD2 in
NZWR. Tempol decreased superoxide presence but led
to an increase in hydrogen peroxide, NAD(P)H oxidase
subunits, and calciﬁcation. LA decreased both superoxide
and hydrogen peroxide and led to a decrease in calciﬁcation
and echogenicity of the valve. These preliminary results
showed that ROS may potentiate calciﬁcation, particularly
in relation to hydrogen peroxide and possibly NAD(P)H
oxidase activity, and pharmacological prevention of ROS
may prevent or decrease calciﬁc burden [19].
4. Conclusions andRecommendations
When properly chosen and implemented, animal models
are a vital tool for the investigation of pathobiological
mechanisms of CAVD and potential therapeutic interven-
tions. Many animal models have been shown to recapitulate12 International Journal of Inﬂammation
important aspects of human CAVD pathobiology, thus
enabling detailed investigations that are otherwise unfeasible
or impossible to conduct in humans. The development
of new models and our improved understanding of the
utility of existing models have quickly advanced the impact
that animal model-based studies are making within this
ﬁeld. Mouse, rabbit, or swine models each oﬀer species-
speciﬁc advantages for the study of CAVD and represent a
fundamentalstepforwardinthetranslationofbasicscientiﬁc
research into clinically relevant and impactful knowledge.
Moving forward, there is a need for improved model
characterization to enable direct comparisons between mul-
tiple studies and aid in interpretation of ﬁndings as they
relatedtohumanCAVD.Ataminimum,thefollowingmodel
parameters necessary for interstudy comparisons should be
provided: (1) animal starting age and weight; (2) full diet
composition, including % kcal contributions; (3) feeding
regime (ad libitum, weight adjusted, or ﬁxed amount, and
growth rate); (4) full plasma lipid proﬁles (TC, HDL, TG,
LDL); (5) background strain(s) used in generating knockout
mice; (6) age and weight at sacriﬁce. Models should have full
histological characterization of lesion progression, including
lesion composition and anatomical location, and valvular
function should be impaired in advanced disease models.
Some mice and rabbit models acquire hemodynamically
signiﬁcant CAVD, but the same has yet to be shown in
swine. However, some swine models develop advanced
atherosclerotic lesions and vascular stiﬀening after eight
months of high-cholesterol diet [112], and therefore valvular
stiﬀening and dysfunction may simply take longer than has
been studied to date [101].
In order to truly understand the relevance of animal
models to human valvular disease, a better understanding
of human CAVD pathogenesis is required. As new insights
into human disease are revealed, animal models and the data
they generate need to be critically reinterpreted. A priority
is to determine whether the extreme hypercholesterolemia
induced in many standard CAVD models faithfully repre-
sents the full progression of human disease. In the future,
ageingmodelsofdiseasemayprovetobethebestatinducing
human-type disease, although time and expense remain
prohibitive. To date, there are two aged mouse models [38,
41]a n do n ea g e dr a b b i tm o d e l[ 83] that maintain moderate
cholesterol levels and induce functional disease. Swine mod-
els of familial or mild diet-induced hypercholesterolemia
could provide the best match with cholesterol levels in
humans and when aged, may produce advanced disease.
Perhaps the most promising application of well-char-
acterized animal models is to investigate CAVD-initiating
events and the mechanisms of its progression to late-stage
functional impairment. Animal models clearly oﬀer a sig-
niﬁcant advantage in this context, as it is diﬃcult to clearly
identify disease stage or control for confounding factors in
human autopsy or transplant samples. CAVD initiation and
early progression have largely been ignored to date, but
would provide the richest insight into therapeutic targets to
arrest calciﬁcation before the putative “point of no return”
when calciﬁc burden cannot be reversed. Inﬂammation,
ECM adaptation, and early procalciﬁc signalling likely play
important roles, but have not yet been studied in detail.
There has been little focus on, for example, the mechanisms
that regulate macrophage/T-cell inﬁltration, inﬂammatory
signalling cascades, or layer-speciﬁc ECM changes and
their role in modulating VIC phenotype. It is prospective
investigations of molecular regulators of valve homeostasis
and disease progression like these that will beneﬁt from well-
characterized and validated animal models and are most
likely to lead to the discovery of novel treatments for CAVD.
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